News | May 24, 2024
Merck to showcase advances in the science of cancer with new data presented at ASCO 2024
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Global Phase-3 study initiation expected in the second half of 2024
Sun Pharma's Dadra facility receives OAI status from US FDA
Subscribe To Our Newsletter & Stay Updated
